{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000000", "text": "# ICCR-Ovary-2nd-edn-v1-bookmark", "section": "ICCR-Ovary-2nd-edn-v1-bookmark", "page_from": null, "page_to": null, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "20863b60f2d5b21c2ca9f830ca5c7e36a7855a6c6b52aafaaed38fadb88853a3"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000001", "text": "Ovary, Fallopian Tube and\nPrimary Peritoneal Carcinoma\nHistopathology Reporting Guide\nSponsored by\n\nVersion 2.0 Published September 2021                                       ISBN: 978-1-922324-25-2\n       Page 1 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\nCLINICAL INFORMATION (select all that apply) (Note 1)\nInformation not provided\nKnown gene predisposition (e.g., BRCA1, BRCA2, Lynch\nsyndrome), specify\nPrior neoadjuvant therapy, specify\nSPECIMEN(S) SUBMITTED (select all that apply) (Note 2)\nSPECIMEN INTEGRITY (select all that apply) (Note 3)\n\n(Required only if ovary(ies)/fallopian tube(s) are submitted)\nLeft fallopian tube\nOvary\nFallopian tube\nTUMOUR SITE (select all that apply) (Note 4)\nTUMOUR DIMENSIONS (Note 5)\n\n(If separate tumours specify dimensions for each site)\nx\n              mm\n              mm\nx\n             mm\nMACROSCOPIC DESCRIPTION OF OMENTUM (Note 6)\n(Required only if omentum submitted)\nx\n              mm\n               mm\nx\n              mm\nOmental involvement\n\t               mm\nOther, specify\nRight fallopian tube\nRight ovary\nRight\nPeritoneum\nOther, specify\nFimbrial\nNon-fimbrial\nNot involved\nInvolved\nSerosa intact\nSerosa ruptured", "section": "Primary Peritoneal Carcinoma", "page_from": 1, "page_to": 1, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "7c911277823d7fb80c0128fc947c7bd96f6ae5ba630a8eaaa5db827613eb32f8"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000002", "text": "Omental involvement\n\t               mm\nOther, specify\nRight fallopian tube\nRight ovary\nRight\nPeritoneum\nOther, specify\nFimbrial\nNon-fimbrial\nNot involved\nInvolved\nSerosa intact\nSerosa ruptured\n     Information not provided\n     Preoperatively\n     Intraoperatively\nTumour on serosal surface\nFragmented specimen\nOther, specify\nSerosa intact\nSerosa ruptured\n     Information not provided\n     Preoperatively\n     Intraoperatively\nTumour on serosal surface\nFragmented specimen\nOther, specify\nIndeterminate\nNo macroscopically visible tumour\nOther, specify\nLeft\nRight\nLaterality not specified\nLeft\nRight\nLaterality not specified\nLeft\nFimbrial\nNon-fimbrial\nLaterality not specified\nLeft\nRight\nLaterality not specified\nLeft\nRight\nLaterality not specified\nLeft ovary\nOmentum dimensions\nMaximum dimension of\nlargest tumour deposit\nNot specified\nOvary\nOvarian cystectomy\nFallopian tube\nUterus\nCervix\nOmentum\nPeritoneal biopsies\nPeritoneal washings/peritoneal fluid\nLymph nodes, specify site(s)\nOvarian capsule intact\nOvarian capsule ruptured\n     Information not provided\n     Preoperatively\n     Intraoperatively\nTumour on surface\nFragmented specimen\nOther, specify\nOvarian capsule intact", "section": "Primary Peritoneal Carcinoma", "page_from": 1, "page_to": 1, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "9b8bf80c5ea749856921e4e9c6c84314fbfdd3c453d2614148f7c23e41e01a89"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000003", "text": "Ovarian capsule intact\nOvarian capsule ruptured\n     Information not provided\n     Preoperatively\n     Intraoperatively\nTumour on surface\nFragmented specimen\nOther, specify\nOvarian capsule intact\nOvarian capsule ruptured\n    Information not provided\n    Preoperatively\n    Intraoperatively\nTumour on surface\nFragmented specimen\nOther, specify\nFamily/Last name\nGiven name(s)\nPatient identifiers\nDate of request\nAccession/Laboratory number\nElements in black text are CORE. Elements in grey text are NON-CORE.\nDate of birth\nDD – MM – YYYY\nDD – MM – YYYY\nSCOPE OF THIS DATASET\nindicates single select values\nindicates multi-select values", "section": "Primary Peritoneal Carcinoma", "page_from": 1, "page_to": 1, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "7915b8adf98e13a49809d4bc2f93c4cc5719a0567d2898fa85195d025776d61e"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000004", "text": "Ovary, Fallopian Tube and Primary Peritoneal Carcinoma\nVersion 2.0 Published September 2021                                       ISBN: 978-1-922324-25-2\n       Page 2 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\nCARCINOSARCOMA COMPONENTS (select all that apply)\n(Note 10)\nEpithelial\n\n    %\n\n%\nExpansile\nInfiltrative/destructive\nHISTOLOGICAL TUMOUR GRADE (Note 11)\nBORDERLINE TUMOUR - SPECIAL FEATURES (Note 12)\n(Applicable only if borderline tumour is identified)\nMicropapillary architecture for serous borderline\ntumour (at least 5 mm in one dimension)\nMicroinvasion (upper limit 5 mm)\nIntraepithelial carcinoma for mucinous borderline\ntumour\nImplants for serous and seromucinous borderline\ntumour (select all that apply)\nEpithelial\nDesmoplastic\nSite(s)\nPelvic\nAbdominal\nEndometrioid carcinomas\nBLOCK IDENTIFICATION KEY (Note 7)\n\n(List overleaf or separately with an indication of the nature\n\nand origin of all tissue blocks)\nList components\nPercentage\nType\nList components\nHomologous\nHeterologous\nPercentage\nSarcomatous\nNot identified\nPresent\nNon-invasive implants\nNot identified\nPresent\nInvasive implants/Extra-ovarian low grade serous\ncarcinoma\nNot identified", "section": "Page 2 of 40", "page_from": 2, "page_to": 2, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "339ce24a4142c79b27aa25bb80b6cf9b23ae35de4964fe6b5e4a31cb6622b7e7"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000005", "text": "Homologous\nHeterologous\nPercentage\nSarcomatous\nNot identified\nPresent\nNon-invasive implants\nNot identified\nPresent\nInvasive implants/Extra-ovarian low grade serous\ncarcinoma\nNot identified\nPresent\nIndeterminate\nNot identified\nPresent\nSite(s)\nPelvic\nAbdominal\nPelvic\nAbdominal\nSEROUS TUBAL INTRAEPITHELIAL CARCINOMA (STIC)\n\n(Required only if fallopian tube(s) are submitted) (Note 13)\nLeft fallopian tube\nCannot be assessed\nNot identified\nPresent (select all that apply)\nRight fallopian tube\nFimbrial\nNon-fimbrial\nCannot be assessed\nNot identified\nPresent (select all that apply)\nFimbrial\nNon-fimbrial\nGX: Cannot be assessed\nG1: Well differentiated\nG2: Moderately differentiated\nG3: Poorly differentiated\nSite(s)\nPATTERN OF INVASION (Note 9)\n\n(Applicable for mucinous carcinomas only)\nMucinous carcinomas\nSerous borderline tumour\nLow grade serous carcinoma\nHigh grade serous carcinoma\nMucinous borderline tumour\nMucinous carcinoma\nEndometrioid borderline tumour\nEndometrioid carcinoma\nClear cell borderline tumour\nClear cell carcinoma\nSeromucinous borderline tumour\nBorderline Brenner tumour\nMalignant Brenner tumour\nMesonephric-like adenocarcinoma\nCarcinoma, undifferentiated", "section": "Page 2 of 40", "page_from": 2, "page_to": 2, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "5fe4827d1228126b9c1e26ca491fbf399139b85a4ea8e2789de2a20fec51615c"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000006", "text": "Clear cell borderline tumour\nClear cell carcinoma\nSeromucinous borderline tumour\nBorderline Brenner tumour\nMalignant Brenner tumour\nMesonephric-like adenocarcinoma\nCarcinoma, undifferentiated\nDedifferentiated carcinoma\nCarcinosarcoma\nMixed carcinoma\nOther, specify\nNot identified\nPresent\nGX: Cannot be assessed\nG1: Well differentiated\nG2: Moderately differentiated\nG3: Poorly differentiated\nNot identified\nPresent\nHISTOLOGICAL TUMOUR TYPE (select all that apply) (Note 8)\n(Value list based on the World Health Organization\nClassification of Female Genital Tumours (2020))", "section": "Page 2 of 40", "page_from": 2, "page_to": 2, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "9e941db28d12d73cd4004806cc7777c2104b4359c26d09310ba4a9d574fc31e9"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000007", "text": "Ovary, Fallopian Tube and Primary Peritoneal Carcinoma\nVersion 2.0 Published September 2021                                       ISBN: 978-1-922324-25-2\n       Page 3 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\nOmentum\nLevel of involvement\nMacroscopic\nOther involved organs(s)/sites(s), specify\nLYMPH NODE STATUS (Note 16)\nRegional\nLeft pelvic\n\nNumber of nodes examined\na\n\nNumber of positive nodes\na\nRight pelvic\n\nNumber of positive nodes\na\nPara-aortic\n\nNumber of positive nodes\na\n\t               mm\nMaximum dimension of largest\ndeposit in regional node\nRight fallopian tube\nHISTOLOGICAL SITES OF TUMOUR INVOLVEMENT (Note 4)\nLeft ovary\nRight ovary\nLeft fallopian tube\nPERITONEAL CYTOLOGY (Note 14)\nNot submitted\nIndeterminate\nPositive\nNegative\nNot applicable\nCannot be assessed\nNot involved\nInvolved (select all that apply)\nNot applicable\nCannot be assessed\nNot involved\nInvolved\nPeritoneum (including uterine serosa)\nSite(s)\nPelvis, specify site(s)\nAbdomen, specify site(s)\na In some cases it may not be possible to record the actual number of\n\t nodes due to fragmentation of the specimen.\nNon-regional\nSite 1\n\nNumber of positive nodes\na\n\nSite 2", "section": "Page 3 of 40", "page_from": 3, "page_to": 3, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "a864f30513fec8f6c546e71ccd500cb2f15a3bffd826d0a0255b5ad81e40f745"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000008", "text": "Abdomen, specify site(s)\na In some cases it may not be possible to record the actual number of\n\t nodes due to fragmentation of the specimen.\nNon-regional\nSite 1\n\nNumber of positive nodes\na\n\nSite 2\n\nNumber of positive nodes\na\n\nMicroscopic\nRESPONSE TO NEOADJUVANT THERAPY (Note 15)\nCOEXISTENT PATHOLOGY/PRECURSOR LESIONS (Note 17)\nPresent, specify\nANCILLARY STUDIES (Note 18)\nImmunohistochemistry, specify test(s) and result(s)\n\nMolecular findings, specify test(s) and result(s)\nNot performed\nPerformed (select all that apply)\n\nOther, specify test(s) and result(s)\nNumber of nodes examined\na\nUterus\nNumber of nodes examined\na\nNumber of nodes examined\na\nCannot be assessed\nNo prior treatment\nNo definite or minimal response identified (chemotherapy\nresponse score (CRS 1))\nModerate response identified (CRS 2)\nMarked response with no or minimal residual cancer\n(CRS 3)\nNone identified\nNumber of nodes examined\na\nNot applicable\nCannot be assessed\nNot involved\nInvolved (select all that apply)\nSite(s)\nMyometrium\nEndometrium\nCervix\nNot applicable\nCannot be assessed\nNot involved\nInvolved\nNot applicable\nCannot be assessed\nNot involved\nInvolved\nNot applicable\nCannot be assessed\nNot involved\nInvolved", "section": "Page 3 of 40", "page_from": 3, "page_to": 3, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "17d69bd4f70b279147807a3b2267de2aa311f136ca03146b4068fb5d0308df64"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000009", "text": "Myometrium\nEndometrium\nCervix\nNot applicable\nCannot be assessed\nNot involved\nInvolved\nNot applicable\nCannot be assessed\nNot involved\nInvolved\nNot applicable\nCannot be assessed\nNot involved\nInvolved\nCannot be assessed\nNo nodes submitted or found\nNot involved\nInvolved (select all that apply)\nNot applicable\nCannot be assessed\nNot involved\nInvolved", "section": "Page 3 of 40", "page_from": 3, "page_to": 3, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "b88ca4180732f7a7eb9ee5bf2f253c70de9c3f631968c61f65e4ecdacc8951e7"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000010", "text": "Ovary, Fallopian Tube and Primary Peritoneal Carcinoma\nVersion 2.0 Published September 2021                                       ISBN: 978-1-922324-25-2\n       Page 4 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\nPROVISIONAL PATHOLOGICAL STAGING (Note 19)\nTNM Staging (UICC TNM 8th edition 2016)\nc\nm \t - \t multiple primary tumours\nr   \t - \t recurrent\ny  \t - \t post-therapy\nPrimary tumour (pT)\nN1\n\t Retroperitoneal lymph node metastasis only\n\t N1a\t Lymph node metastasis not more than 10 mm in\n\n\t greatest dimension\n\t N1b\t Lymph node metastasis more than 10 mm in greatest\n\t dimension\n \t T3a any N\n\n\t Microscopic extrapelvic (above the pelvic brim)\n\n\t peritoneal involvement with or without retroperitoneal\n\t lymph node, including bowel involvement\n \t T3b any N\n\nMacroscopic peritoneal metastasis beyond pelvic\nbrim 2 cm, or less in greatest dimension, including\nbowel involvement outside the pelvis with or without\nretroperitoneal nodes\n \t T3c any N\n\nPeritoneal metastasis beyond pelvic brim more than\n2 cm in greatest dimension and/or retroperitoneal\nlymph node metastasis (includes extension of tumour\nto capsule of liver and spleen without parenchymal", "section": "Page 4 of 40", "page_from": 4, "page_to": 4, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "1383303301f9c2b58ed2004875e9be1a15ca4e0114703ba7bd5a5648aae919c0"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000011", "text": "2 cm in greatest dimension and/or retroperitoneal\nlymph node metastasis (includes extension of tumour\nto capsule of liver and spleen without parenchymal\ninvolvement of either organ)\nRegional lymph nodes (pN)\nc\t Reproduced with permission. Source: UICC TNM Classification of\n\t Malignant Tumours, 8th Edition, eds by James D. Brierley, Mary K.\n\n\t Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley\n\t (incorporating any errata published up until 6th October 2020).\nFIGO (2014 edition)\nb\nSite of primary tumour\nb\tReprinted from Int J Gynaecol Obstet., Volume 124, Prat J and FIGO\n\t Committee on Gynecologic Oncology, Staging classification for cancer\n\t of the ovary, fallopian tube, and peritoneum, pages 1-5, 2014, with\n\t permission from Wiley.\nRepresentative blocks for ancillary studies, specify\nthose blocks best representing tumour and/or normal tissue\nfor further study\n\nANCILLARY STUDIES (Cont.) (Note 18)\nTNM Descriptors (only if applicable) (select all that apply)\nPrimary tumour, ovary (OV)\nPrimary tumour, fallopian tube (FT)\n\tPrimary tumour, peritoneum (P)\n\nUndesignated: site of primary tumour cannot be\nassessed (X)\nI\nTumour is confined to ovaries or fallopian tube(s)\n\t IA", "section": "Page 4 of 40", "page_from": 4, "page_to": 4, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "006154c8463b58b272b53ea2d6ef98250ff4a76daec696065ccbec1086bd423c"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000012", "text": "Primary tumour, fallopian tube (FT)\n\tPrimary tumour, peritoneum (P)\n\nUndesignated: site of primary tumour cannot be\nassessed (X)\nI\nTumour is confined to ovaries or fallopian tube(s)\n\t IA\nTumour limited to 1 ovary (capsule intact) or\n\nfallopian tube; no tumor on ovarian or fallopian\n\ntube surface; no malignant cells in the ascites or\n\nperitoneal washings\n\t IB\nTumour limited to both ovaries (capsules intact) or\n\nfallopian tubes; no tumour on ovarian or fallopian\n\ntube surface; no malignant cells in the ascites or\n\nperitoneal washings\n\t IC\nTumour limited to 1 or both ovaries or fallopian\n\ntubes,with any of the following:\n\nIC1 Surgical spill\n\nIC2\t Capsule ruptured before surgery or tumour on\n                 ovarian or fallopian tube surface\n\nIC3\t Malignant cells in the ascites or peritoneal\n                 washings\nII\nTumour involves 1 or both ovaries or fallopian tubes\n\nwith pelvic extension (below pelvic brim) or primary\n\nperitoneal cancer\n\t IIA \t Extension and/or implants on uterus and/or fallopian\n\ntubes and/or ovaries\n\t IIB \t Extension to other pelvic intraperitoneal tissues\nIII\nTumour involves 1 or both ovaries or fallopian tubes,", "section": "Page 4 of 40", "page_from": 4, "page_to": 4, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "3ffd948e1b5b676b35bc5bc2a72ebd81434e66d25b940120322bb02def95d97b"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000013", "text": "IIA \t Extension and/or implants on uterus and/or fallopian\n\ntubes and/or ovaries\n\t IIB \t Extension to other pelvic intraperitoneal tissues\nIII\nTumour involves 1 or both ovaries or fallopian tubes,\n\nor primary peritoneal cancer, with cytologically or\n\nhistologically confirmed spread to the peritoneum\n\noutside the pelvis and/or metastasis to the\n\nretroperitoneal lymph nodes\n\nIIIA1\t\tPositive retroperitoneal lymph nodes only\n\n\t(cytologically or histologically proven):\n\n\t IIIA1(i)  Metastasis up to 10 mm in greatest\n\t              dimension\n\n\t IIIA1(ii)\t Metastasis more than 10 mm in\n\n        greatest dimension\n\n\tIIIA2\t Microscopic extrapelvic (above the pelvic brim)\n\n\tperitoneal involvement with or without positive\n\n\tretroperitoneal lymph nodes\n\t IIIB \tMacroscopic peritoneal metastasis beyond the pelvis\n\nup to 2 cm in greatest dimension, with or without\n\nmetastasis to the retroperitoneal lymph nodes\n\t IIIC \tMacroscopic peritoneal metastasis beyond the pelvis\n\nmore than 2 cm in greatest dimension, with or\n\nwithout metastasis to the retroperitoneal lymph\n\nnodes (includes extension of tumor to capsule of\n\nliver and spleen without parenchymal involvement of\n\neither organ)\nIV", "section": "Page 4 of 40", "page_from": 4, "page_to": 4, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "f44a1973ed1a98a8d6d06cb0a5ba612feff76b3569e4e2bbbfeb315236de5f83"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000014", "text": "without metastasis to the retroperitoneal lymph\n\nnodes (includes extension of tumor to capsule of\n\nliver and spleen without parenchymal involvement of\n\neither organ)\nIV\nDistant metastasis excluding peritoneal metastases\n\t IVA\t Pleural effusion with positive cytology\n\t IVB\t Parenchymal metastases and metastases to extra\n\nabdominal organs (including inguinal lymph nodes\n\nand lymph nodes outside of the abdominal cavity)\nTX\nPrimary tumour can not be assessed\nT0\nNo evidence of primary tumour\nT1\nTumour limited to the ovaries (one or both) or\nfallopian tube(s)\n\t T1a\t Tumour limited to one ovary (capsule intact) or\nfallopian tube; capsule intact, no tumor on ovarian\nsurface or fallopian tube surface; no malignant cells\nin ascites or peritoneal washings\n\t T1b \t Tumour limited to both ovaries or fallopian tubes;\ncasule intact, no tumour on ovarian or fallopian tube\nsurface; no malignant cells in ascites or peritoneal\nwashings\n\t T1c\nTumour limited to one or both ovaries or fallopian\ntubes with any of the following:\n\nT1c1 Surgical spill\n\nT1c2 Capsule ruptured before surgery or tumour on\novarian or fallopian tube surface\n\nT1c3\t Malignant cells in ascites or peritoneal washings\nT2", "section": "Page 4 of 40", "page_from": 4, "page_to": 4, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "142c75473205ef2bdc683a8cb26e0c774673cef96d8c772c9c0d7a72855bf30a"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000015", "text": "tubes with any of the following:\n\nT1c1 Surgical spill\n\nT1c2 Capsule ruptured before surgery or tumour on\novarian or fallopian tube surface\n\nT1c3\t Malignant cells in ascites or peritoneal washings\nT2\nTumour involves one or both ovaries or fallopian\ntubes with pelvic extension (below pelvic brim) or\nprimary peritoneal cancer\n\t T2a \t Extension and/or implants on uterus and/or fallopian\ntube(s) and/or ovary(ies)\n\t T2b \t Extension to other pelvic tissues, including bowel\nwithin the pelvis\nT3 and/or N1\n\nTumour involves one or both ovaries or fallopian\ntubes or primary peritoneal carcinoma with\ncytologically or histologically confirmed spread to the\nperitoneum outside the pelvis and/or metastasis to\nthe retroperitoneal lymph nodes", "section": "Page 4 of 40", "page_from": 4, "page_to": 4, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "f7305427f2ce8b6ea2b358f2c1d7ee6a5a1ff4dd5f22dd4248a898166aa45e19"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000016", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 5 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nDefinitions\n\nCORE elements\nCORE elements are those which are essential for the clinical management, staging or prognosis\nof the cancer. These elements will either have evidentiary support at Level III-2 or above\n(based on prognostic factors in the National Health and Medical Research Council levels of\nevidence1). In rare circumstances, where level III-2 evidence is not available an element may be\nmade a CORE element where there is unanimous agreement in the expert committee. An\nappropriate staging system e.g., Pathological TNM staging would normally be included as a\nCORE element.\n\nThe summation of all CORE elements is considered to be the minimum reporting standard for a\nspecific cancer.\n\nNON-CORE elements\n\nNON-CORE elements are those which are unanimously agreed should be included in the\ndataset but are not supported by level III-2 evidence. These elements may be clinically", "section": "Definitions", "page_from": 5, "page_to": 5, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "0347dd2864d59ec79b4fcdcf724c525401c2539a01761cab9bbf5196813b1964"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000017", "text": "NON-CORE elements\n\nNON-CORE elements are those which are unanimously agreed should be included in the\ndataset but are not supported by level III-2 evidence. These elements may be clinically\nimportant and recommended as good practice but are not yet validated or regularly used in\npatient management.\n\nKey information other than that which is essential for clinical management, staging or\nprognosis of the cancer such as macroscopic observations and interpretation, which are\nfundamental to the histological diagnosis and conclusion e.g., macroscopic tumour details,\nmay be included as either CORE or NON-CORE elements by consensus of the Dataset Authoring\nCommittee.\n       Back\n\nScope\n\nThe dataset has been developed for the pathology reporting of resection specimens of primary borderline and\nmalignant epithelial tumours of the ovary, fallopian tubes and peritoneum. It does not include non-epithelial\novarian neoplasms such as germ cell or sex cord stromal tumours or other primary peritoneal neoplasms such\nas mesothelioma.2 In those rare cases where more than one primary tumour of different morphological types", "section": "Definitions", "page_from": 5, "page_to": 5, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "7df4094c515f138bbc20bfac4244edddce16a54b8ad13565086a89d165161c66"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000018", "text": "as mesothelioma.2 In those rare cases where more than one primary tumour of different morphological types\nis present, separate datasets should be completed for each neoplasm. These should include all the elements in\nthis dataset, except for lymph node status which does not need to be documented separately for each tumour.\n\nThe 2nd edition of this dataset includes changes to align the dataset with the World Health Organization (WHO)\nClassification of Tumours, Female Genital Tumours, 5th edition, 2020.3 The International Collaboration on\nCancer Reporting (ICCR) dataset includes 5th edition Corrigenda, June 2021.4\nThe authors of this dataset can be accessed here.\n       Back", "section": "Definitions", "page_from": 5, "page_to": 5, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "0dc6a18bb8194839a8b6a848068ae410061daacb957b5860aa2a873e4dfea314"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000019", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 6 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nNote 1 – Clinical information (Non-core)\n\nIt is estimated that approximately 10% of primary tubo-ovarian and peritoneal carcinomas have a genetic\nbasis,5 and this figure may be as high as 17% for high grade serous carcinomas (HGSCs).6 Germline mutations in\nBRCA1 and BRCA2 account for the majority of genetically related cases while up to 10% of patients with Lynch\nsyndrome (LS) will develop ovarian carcinoma.\n\nIt is acknowledged that definitive genetic status is often not known or information about genetic status is not\nprovided to the pathologist at the time of biopsy/surgery. Moreover, this information is not essential for the\nhistological assessment and routine reporting of these tumours. Nevertheless, it is recommended that\navailable information on genetic status be recorded for the following reasons:\n1. High grade serous carcinomas (HGSCs) associated with BRCA mutations (germline or somatic) more", "section": "Definitions", "page_from": 6, "page_to": 6, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "0e003e8578cfee24126f051df3af2fcf4bc60c1da8eb3e73df400ac94d51e04c"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000020", "text": "available information on genetic status be recorded for the following reasons:\n1. High grade serous carcinomas (HGSCs) associated with BRCA mutations (germline or somatic) more\ncommonly show certain morphological features such as solid, pseudoendometrioid or transitional-like\n(‘SET’) architectural patterns, very marked nuclear atypia, and tumour-infiltrating lymphocytes.5,7,8\nThus, pathologists may be able to correlate the histological findings with any genetic data provided,\nbetter chemotherapy response, and consideration of specific therapeutic regimes such as those\nincluding poly ADP ribose polymerase inhibitors (PARPi).5,6,9 Patients with suspected germline BRCA\nmutations and their relatives, may also be referred for genetic testing and counselling in regard to\nappropriate screening for BRCA-related neoplasia, although in many places this is done for all HGSCs\nirrespective of the tumour morphology.\n2. Knowledge of proven or potential hereditary gynaecological cancer predisposition will affect\npathological sampling of macroscopically normal tissues. This is most evident in the setting of", "section": "Definitions", "page_from": 6, "page_to": 6, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "556741fb9f500e04a46f5326e095097415a8f2937d899bba2e2548329dd78673"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000021", "text": "2. Knowledge of proven or potential hereditary gynaecological cancer predisposition will affect\npathological sampling of macroscopically normal tissues. This is most evident in the setting of\nprophylactic ‘risk reduction surgery’, especially in patients with known BRCA1 or BRCA2 mutation,\nwhere complete examination of tubal and ovarian tissues is essential.5 Small, macroscopically occult\ntubal carcinomas, and their in situ precursor - serous tubal intraepithelial carcinoma (STIC) - is much\nmore likely to be identified in this setting.\n\nApproximately 1-2% of all ovarian carcinomas are associated with LS due to a germline mutation in one of the\ngenes encoding the DNA mismatch repair (MMR) proteins.10 In approximately 60% of women with LS, a\ngynaecological tumour (endometrial or ovarian) will represent the sentinel cancer.11 Endometrioid and clear\ncell and endometriosis-associated carcinomas occur more frequently in LS and, therefore,\nimmunohistochemical analysis of MMR proteins or molecular testing for microsatellite instability may be\nconsidered in these tumour types, or if there is relevant personal or family history of additional LS-related\nneoplasia.", "section": "Definitions", "page_from": 6, "page_to": 6, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "a570745806ba3e24c2060741a1e455dccdfed395a960c0c796658597a398c766"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000022", "text": "considered in these tumour types, or if there is relevant personal or family history of additional LS-related\nneoplasia.\n\nPreoperative chemotherapy may significantly alter the gross and microscopic appearance of the tumour and\nresult in difficulties in tumour typing and tumour down-staging. If neoadjuvant chemotherapy is being\nadministered, a pretreatment tissue biopsy is recommended for tumour typing. If this is not possible then the\ndiagnosis of malignancy can be made on cytological examination of ascitic fluid, preferably with\nimmunohistochemistry (IHC) performed on a cell block preparation; however, there are limitations to the\ninterpretation of immunohistochemical markers on cell blocks.12 Markers of value in tumour typing are\ndiscussed in Note 18 ANCILLARY STUDIES.\n       Back\n\nNote 2 – Specimen(s) submitted (Core)\n\nProviding information about the specimen type is regarded as an integral part of the reporting of primary\novarian, tubal and peritoneal cancers. While the nature of the specimens submitted for pathological\nassessment may be deduced from the surgical procedure, specifying the nature of the specimen received", "section": "Definitions", "page_from": 6, "page_to": 6, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "595e0949c7ab33706141edc887c9967f1d481677bf5072a8ed1ab9a795f001f3"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000023", "text": "assessment may be deduced from the surgical procedure, specifying the nature of the specimen received\nprovides complementary information and confirmation that entire organs have been resected and submitted.\n       Back", "section": "Definitions", "page_from": 6, "page_to": 6, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "694d383f9c91650d289e36039290c45b79d0c11b52dbd1c224c304628a553c59"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000024", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 7 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nNote 3 – Specimen integrity (Core)\n\nAssessment of the integrity of the specimen (ovary or tube) is important, particularly for substaging of organ-\nconfined disease (Stage I). Core information should include whether the ovarian capsule or tubal serosa is\nintact or ruptured, and also if there is tumour on the surface, or whether the tumour was received fragmented\nor intact. In case of capsule rupture, it is recommended to try to ascertain if rupture occurred before or during\nsurgery (this is important in substaging International Federation of Gynaecology and Obstetrics (FIGO) Stage IC\ndisease).13 Note that if the specimen ruptures within a bag during laparoscopic removal, or is cut into in the\noperating room, after removal from the patient, such that the peritoneal cavity is not exposed to the contents\nof the mass, it should be considered to be not ruptured i.e., ’intact’, for surgical pathology reporting purposes.", "section": "Definitions", "page_from": 7, "page_to": 7, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "6c130f15aff6fcaf9a79c4e06a1e7abab2db5829962d7360d972ef381cb48219"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000025", "text": "of the mass, it should be considered to be not ruptured i.e., ’intact’, for surgical pathology reporting purposes.\n\nAccording to the 2014 FIGO Staging System for ovarian, tubal and primary peritoneal cancer,13 ovarian\ncapsular or tubal serosal rupture before surgery is considered Stage IC2 while intraoperative rupture is Stage\nIC1. There is some controversy as to whether rupture during surgery worsens the prognosis in the absence of\nsurface excrescences, ascites or positive washings. Some studies showed a higher risk of recurrence in\nassociation with intraoperative ovarian capsular rupture,14,15 while others did not.16-18\n\nA 2014 meta-analysis assessed the impact of intraoperative rupture on prognosis, after analysing nine eligible\nstudies which included 2,382 patients.13 Patients with preoperative capsular rupture showed poorer\nprogression-free survival (PFS) than those with no rupture or intraoperative rupture. In sub-analyses,\npreoperative rupture was associated with a worse prognosis, and intraoperative rupture had a poorer PFS\nthan no rupture. However, no difference in PFS was found between intraoperative rupture and no rupture in", "section": "Definitions", "page_from": 7, "page_to": 7, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "7f64a046734ad370d6e44e7c49059d53fc5a04d18f01b50da820339fc4b94792"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000026", "text": "than no rupture. However, no difference in PFS was found between intraoperative rupture and no rupture in\npatients who underwent a complete surgical staging operation, with or without adjuvant platinum-based\nchemotherapy. In a recent large study, the risk associated with intra-operative rupture/Stage IC1 ovarian\ncarcinoma was histotype dependent and greatest for patients with clear cell carcinoma.19\n\nThere is some evidence to suggest that clear cell carcinomas exhibit a higher risk of rupture,20 probably related\nto adhesions to the surrounding tissues, associated with tumour invasion or endometriosis.21 Capsular rupture\nhas also been associated with pregnancy.22\n       Back\n\nNote 4 – Tumour site/Histological sites of tumour involvement (Core)\n\nSites of tumour involvement should be recorded as this is necessary for tumour staging. Although site\nassignment (tube versus ovary versus peritoneum) for clear cell, endometrioid, low grade serous and\nmucinous carcinomas is generally not problematic since almost all arise in the ovary, except for occasional\ncases arising in extraovarian endometriosis, the same is not true for HGSCs.", "section": "Definitions", "page_from": 7, "page_to": 7, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "ab51d2ce587442e7247f796ca5894001e138348fa0664faa893498714fa2fe2d"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000027", "text": "mucinous carcinomas is generally not problematic since almost all arise in the ovary, except for occasional\ncases arising in extraovarian endometriosis, the same is not true for HGSCs.\n\nIt was first recognised in 2001, that a high percentage of so-called ovarian HGSC in women with germline\nBRCA1 mutations arise in the fimbrial end of the fallopian tube.23,24 This was initially reported in risk reducing\nsalpingo-oophorectomy specimens where early pre-invasive HGSCs were much more likely to be present in the\nfallopian tube than ovary. These STICs harbour identical p53 mutations to the extratubal tumour, establishing\nthat they are clonal.25 Comparison of telomere length and centrosome amplification in matched STIC and\novarian HGSC suggests that the STICs develop before the ovarian tumours and are in fact a precursor and not a\nmetastatic focus.26,27 Finally, although numbers are small, early, incidental non-BRCA1/2 associated (sporadic)\nHGSCs are predominantly detected in the fallopian tube mucosa, especially the fimbria, rather than the\novary.28 In summary, there is compelling evidence that the precursors of HGSC originate in the fallopian tube", "section": "Definitions", "page_from": 7, "page_to": 7, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "469b6e35b94cdc6fcc9086ea950cadb966e159743350113dfc93f8bbcf611554"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000028", "text": "ovary.28 In summary, there is compelling evidence that the precursors of HGSC originate in the fallopian tube\nin patients with germline BRCA1 mutations, and there is accumulating and convincing evidence that this is also\ntrue for sporadic HGSC. Assignment of primary site should therefore reflect our current understanding of\nwhere HGSCs originate, based on data from the study of early incidental or pre-invasive HGSC. However, some\ncases of ovarian and primary peritoneal HGSCs do not show STIC lesions or tubal mucosal HGSC despite entire\nsubmission of the grossly normal fallopian tubes for histological evaluation. In a consecutive series of non-", "section": "Definitions", "page_from": 7, "page_to": 7, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "50e1f0b74b07fe73b705ba3320dccd1fe51a35b6a8b0dca953b1bce8ae374624"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000029", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 8 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nuterine HGSCs classified as ovarian or peritoneal based on pre-FIGO 2014 criteria in which the fallopian tubes\nwere examined in their entirety, STICs were identified in 59% of cases, and invasive HGSC of the mucosa of the\nfallopian tube in an additional 15% of cases.13,29 In other cases, the fimbrial end of the fallopian tube was\nobliterated by a tubo-ovarian mass.\n\nAccording to the 2014 FIGO Staging System, the primary site of non-uterine HGSC is designated as ovarian,\ntubal or primary peritoneal.13 In some cases it may not be possible to ascertain the primary site of origin, and\nthese should be categorised as ‘undesignated’ in the new staging system.13 The descriptor ‘tubo-ovarian HGSC’\ncan also be used in practice for those cases of advanced stage HGSC where there is uncertainty about primary\nsite, e.g., pre-treatment biopsy from the omentum. The problems in ascertaining the primary site and the", "section": "Definitions", "page_from": 8, "page_to": 8, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "1a4b5a811e0f32ecbe96bdae4e5fd0917501584898c016db148fbd9635225896"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000030", "text": "site, e.g., pre-treatment biopsy from the omentum. The problems in ascertaining the primary site and the\nvariation in practice amongst pathologists have significant implications for epidemiological studies,\ndetermination of tumour incidence and mortality, data collection by cancer registries and entry into clinical\ntrials. Based on the 2020 WHO Classification,3 recommendations for assigning the site of origin of extra-uterine\nHGSC are provided in the following section. Using these criteria, assignment of primary site is no longer based\non the site of greatest volume/size of tumour but the presence of STIC or tubal mucosa involvement by HGSC\nindicates a fallopian tube origin, as does partial or total obliteration of one or both fallopian tubes by a tumour\nmass. Application of these criteria will be important in ensuring consistency between different pathologists in\nassigning the site of origin of HGSC with obvious important implications for cancer registration and other\nparameters.30\n\nSuggestions for assigning site of origin\nThe following suggestions are not intended to be an exhaustive list nor are they intended to be binding, and", "section": "Definitions", "page_from": 8, "page_to": 8, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "8b95fa2f6d7246c2036fbfd7d829bec56c648bb83d009ec1e14f41481be60f1a"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000031", "text": "parameters.30\n\nSuggestions for assigning site of origin\nThe following suggestions are not intended to be an exhaustive list nor are they intended to be binding, and\nassignment of origin in an individual case (Figure 1) is left to the discretion of the pathologist and the clinical\nteam, ideally in the setting of a multidisciplinary team meeting. Undoubtedly, there will be evolution over time\nin our ability to accurately assign the primary tumour site, but the following are intended as practical\nguidelines for handling cases at the present time:30\n1. The fallopian tubes, or at least their fimbrial ends, should be well sampled – whenever possible - in all\ncases of HGSC by a sectioning and extensively examining the fimbriated end (SEE-FIM)-like protocol25\nto avoid missing this important site of disease, which probably represents the tumour origin in the\nlarge majority of cases.\n2. The presence of STIC, in the absence of invasive HGSC involving the fallopian tube, should be\nconsidered as tubal primary for staging purposes, e.g., points 4 and 7.\n3. The presence of STIC without invasion or extratubal spread should be staged as FIGO Stage IA tubal", "section": "Definitions", "page_from": 8, "page_to": 8, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "50ed00e172a4050f73ece90a6cbc995239be73c28613ab131dc68613a1126c80"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000032", "text": "considered as tubal primary for staging purposes, e.g., points 4 and 7.\n3. The presence of STIC without invasion or extratubal spread should be staged as FIGO Stage IA tubal\ncarcinoma (although these have a favourable prognosis, based on limited experience to date31) but\nwith an annotation that there is no ‘invasive’ carcinoma.\n4. Cases with only STIC in the fallopian tube, ovarian surface involvement or parenchymal involvement\nnot exceeding 5 millimetres (mm) and widespread peritoneal involvement, which would traditionally\nbe categorised as primary peritoneal carcinoma,32 should be classified as tubal primaries.\n5. Cases with HGSC located within the mucosa of the fallopian tube, including its fimbrial end, with or\nwithout STIC in any portion of the fallopian tube and with no, minimal or even substantial ovarian\ninvolvement should be categorised as tubal primaries. Note that the distinction between STIC and\nintramucosal HGSC of the fallopian tube is subjective, with the latter showing a greater degree of\nstratification and architectural complexity.\n6. Cases in which the fallopian tube is not identifiable, having presumably been overgrown by the", "section": "Definitions", "page_from": 8, "page_to": 8, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "280c16139dd6f68ad06d9168d2c769d5ad50c090f3fe012242a38f508d4c6bce"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000033", "text": "stratification and architectural complexity.\n6. Cases in which the fallopian tube is not identifiable, having presumably been overgrown by the\nipsilateral adnexal mass, or the distal end of the fallopian tube is incorporated into a large tubo-\novarian mass should also, based on current understanding, be diagnosed as tubal primaries. It is\nemphasised that a careful effort must be made to identify the tube in all cases.\n7. Cases with a dominant ovarian mass(es) and identifiable fallopian tubes with STIC should be classified\nas tubal primaries.\n8. Cases with a dominant ovarian mass(es) and identifiable fallopian tubes without STIC or mucosal\ninvolvement by HGSC, after SEE-FIM, should be classified as ovarian primaries.", "section": "Definitions", "page_from": 8, "page_to": 8, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "835f069e0884715945d4e9e3b001580548412957647bc61ef2a2c08719d6ef9c"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000034", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 9 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\n9. Cases should be categorised as primary peritoneal carcinoma by the conventional criteria below3 and\nonly after complete histological examination of the fallopian tubes (including the non-fimbrial\nportions) has excluded the presence of STIC or a small tubal HGSC or ovarian involvement by HGSC.\n10. All cases classified as ‘undesignated’ for FIGO staging purposes should be further described as ‘tubo-\novarian’ or ‘tubal/ovarian’ to distinguish them from serous carcinoma originating in the uterus. Using\nthe suggestions presented here, these should represent a small proportion of HGSC.\n11. Cases with unilateral or bilateral HGSC in the ovary and/or STIC or HGSC in the tube but with an\nendometrial serous intraepithelial or invasive carcinoma should be carefully evaluated for an\nendometrial versus a tubo-ovarian primary (WT1 may be of value in such cases - see Note 18", "section": "Definitions", "page_from": 9, "page_to": 9, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "ddc4a966166b7968180db670e6b3af8c57a5bf729332744f3339b7da6002fcdc"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000035", "text": "endometrial serous intraepithelial or invasive carcinoma should be carefully evaluated for an\nendometrial versus a tubo-ovarian primary (WT1 may be of value in such cases - see Note 18\nANCILLARY STUDIES, to distinguish between ovarian and uterine carcinoma). The majority of such\ncases will represent adnexal metastases from an endometrial serous carcinoma.33\n\nFigure 1: High grade serous carcinoma: determining the primary site of origin. Serous tubal intraepithelial\ncarcinoma (STIC).\na Failure to detect the tubal fimbria implies overgrowth by tumour.\nb Apply criteria as specified in the commentary.\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n       Back\n\nNote 5 – Tumour dimensions (Non-core)\n\nThere is little or no published evidence to suggest that size of the primary tumour is of prognostic significance,\nand size is not important for staging or management. The principal reason for recording the tumour\ndimensions, especially the maximum diameter, is to provide evidence that the tumour has been adequately\nsampled for histology. There are no evidence-based guidelines as to the optimal sampling of solid or cystic", "section": "Definitions", "page_from": 9, "page_to": 9, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "826050a5cebb38fd779c7cb6671e7a9430d02939339e56b875225efba2df9cd9"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000036", "text": "sampled for histology. There are no evidence-based guidelines as to the optimal sampling of solid or cystic\novarian tumours. By convention, however, most pathologists sample one block per 10 mm of maximum\ntumour diameter in solid tumours. These same recommendations appear in cancer datasets for tumours at a\nrange of other anatomical sites.\nHigh grade serous carcinoma:\nDetermining the primary site of origin", "section": "Definitions", "page_from": 9, "page_to": 9, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "ea557567cc0255ce43a15a803e3e24eae894105bf6b93621469759e410d881a8"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000037", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 10 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nAdequate sampling of ovarian tumours is important for a number of reasons; for example, to identify foci of\nmicroinvasion or invasion in borderline tumours, foci of sarcoma in an ovarian carcinoma (carcinosarcoma), or\nfoci of undifferentiated carcinoma in an endometrioid carcinoma (dedifferentiated carcinoma).\n\nIt is recognised that ovarian mucinous neoplasms may exhibit considerable intratumoural heterogeneity with\nan admixture of benign, borderline and malignant areas. One study which assessed the ‘adequacy’ of sampling\nin epithelial ovarian neoplasms,34 confirmed mucinous carcinomas to display more histological variation than\nserous carcinomas. The authors concluded that more extensive sampling was required in borderline tumours\nto exclude foci of invasion. According to the recommendations of the 2004 Bethesda Workshop for borderline\novarian tumours,35 all borderline tumours should be well sampled – at least two sections per 10 mm (excluding", "section": "Definitions", "page_from": 10, "page_to": 10, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "52a1ba671c4d71bff7d79058e7b2c25f512f7a8e01f27994f5c5f0dddd0304ce"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000038", "text": "ovarian tumours,35 all borderline tumours should be well sampled – at least two sections per 10 mm (excluding\nsmooth-walled cystic foci) with the exception that borderline tumours of less than 100 mm should be sampled\nwith one block per 10 mm of maximum tumour diameter. The recommendation that there should be more\nextensive sampling of larger tumours, especially those of mucinous type, reflects their greater likelihood of\nharbouring foci of invasive carcinoma. Additional sampling of mucinous borderline tumours is also\nrecommended when histological features such as intraepithelial carcinoma or microinvasion are identified in\nthe original sections. Similarly, additional sampling in serous borderline tumours is recommended when\nmicropapillary areas or microinvasion are present in initial sections since such neoplasms are more likely to\nharbour invasive foci.\n\nIn mucinous ovarian tumours, tumour size may be helpful in determining whether the ovarian neoplasm is\nprimary or metastatic. Unilateral mucinous carcinomas ≥100 mm in diameter are more likely to be primary\nthan metastatic.36,37\n       Back\n\nNote 6 – Macroscopic description of omentum (Core)", "section": "Definitions", "page_from": 10, "page_to": 10, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "7c74ee39e896dce200ce3e2604615c219b1bf84468b474db6c40e29144314e82"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000039", "text": "primary or metastatic. Unilateral mucinous carcinomas ≥100 mm in diameter are more likely to be primary\nthan metastatic.36,37\n       Back\n\nNote 6 – Macroscopic description of omentum (Core)\n\nThree dimensions of the omentum should be provided in the pathology report to document the size of the\nspecimen received for pathological examination. This may be useful in certain scenarios to direct the need for\nfurther surgery. For example, if initially only an omental biopsy was performed, further surgery may be\nundertaken to remove the remainder of the omentum. The size of the specimen is also helpful to determine\nthe extent of sampling for histologic examination. No standardised guidelines have been developed for\nsampling omental specimens in cases of ovarian carcinoma or borderline tumours. However, in the setting of a\ngrossly involved omentum, submitting one block for histologic examination is probably sufficient.38,39 In\npatients who have received neoadjuvant chemotherapy, where histological assessment of tumour response to\ntherapy is recommended (see Note 15 RESPONSE TO NEOADJUVANT THERAPY), examination of 4-6 blocks of", "section": "Definitions", "page_from": 10, "page_to": 10, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "9d1e10510d80850e8985154e3ab6b5c733351ce537bdfefed2b82fc7e5d053ec"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000040", "text": "therapy is recommended (see Note 15 RESPONSE TO NEOADJUVANT THERAPY), examination of 4-6 blocks of\nomentum is suggested. For grossly negative omental specimens the sampling recommendations are variable –\nsampling of 3-5 blocks is recommended in one study,39 other studies suggest at least one block for every 20\nmm of maximum omental dimension.40 Taking this information into account, 4-6 blocks in cases where the\nomentum is grossly negative in patients with an ovarian carcinoma or borderline tumour is recommended.\n\nThe size of the largest omental tumour deposit should be recorded in the pathology report. This is critical for\ndetermining the pathological stage.3,13 Microscopic tumour which is not grossly evident, macroscopically\nevident tumour ≤20 mm, and macroscopically evident tumour >20 mm, correspond to FIGO Stages IIIA2, IIIB,\nand IIIC, respectively.13\n       Back", "section": "Definitions", "page_from": 10, "page_to": 10, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "1993e730e1bd9da1633e69fc01ae500719f96689ddcd5b0dde7d5c2c83a7bb24"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000041", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 11 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nNote 7 – Block identification key (Non-core)\n\nThe origin/designation of all tissue blocks should be recorded, and it is preferable to document this\ninformation in the final pathology report. This is particularly important should the need for internal or external\nreview arise. The reviewer needs to be clear about the origin of each block in order to provide an informed\nspecialist opinion. If this information is not included in the final pathology report, it should be available on the\nlaboratory computer system and relayed to the reviewing pathologist. It may be useful to have a digital image\nof the specimen and record of the origin of the tumour blocks in some cases.\n\nRecording the origin/designation of tissue blocks also facilitates retrieval of blocks for further\nimmunohistochemical or molecular analysis, research studies or clinical trials.\n       Back\n\nNote 8 – Histological tumour type (Core)", "section": "Definitions", "page_from": 11, "page_to": 11, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "ef4aa388e4b65053ee93ed3db962e8cd5a062517b821a2162d3d339c053b20c8"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000042", "text": "immunohistochemical or molecular analysis, research studies or clinical trials.\n       Back\n\nNote 8 – Histological tumour type (Core)\n\nAll tubo-ovarian epithelial malignancies and borderline tumours should be typed according to the 2020 WHO\nClassification of Tumours, Female Genital Tumours, 5th edition (Tables 1-3).3 There are five major histotypes of\nprimary ovarian carcinoma: low grade serous, high grade serous, clear cell, endometrioid and mucinous.41-44\nThere are also other uncommon minor types listed in the 2020 WHO Classification including malignant Brenner\ntumour, mesonephric-like and undifferentiated carcinoma.3 As seromucinous carcinoma is considered a\nmorphologic variant of endometrioid carcinoma, it has thus been removed from the updated 2020 WHO\nClassification.3 Carcinomas formerly diagnosed as seromucinous carcinoma are now included in the\nendometrioid category. Carcinosarcoma is a mixed epithelial and mesenchymal malignancy but is included in\nthe category of epithelial malignancies in this dataset and in the 2020 WHO Classification since most are of\nepithelial origin and histogenesis (epithelial mesenchymal transition).3,45", "section": "Definitions", "page_from": 11, "page_to": 11, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "94ba2579af83b852eb08573543bfa9f6e7840b786445519f188e29bc11dc8129"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000043", "text": "the category of epithelial malignancies in this dataset and in the 2020 WHO Classification since most are of\nepithelial origin and histogenesis (epithelial mesenchymal transition).3,45\n\nAlthough management of ovarian carcinoma is, at present, largely dependent on tumour stage and grade,\naccurate typing will almost certainly become more important in the future with the introduction of targeted\ntherapies and specific treatments for different tumour types. This is in part because, although clinically often\nconsidered as one disease, there is an increasing realisation that the different histotypes of ovarian carcinoma\nhave different origins, pathogenesis, are associated with distinct molecular alterations, and have a different\nnatural history, response to traditional chemotherapy, and prognosis.41-44 Tumour typing may also be\nimportant in identifying or initiating testing for an underlying genetic predisposition. For example, HGSC may\nbe associated with underlying BRCA1/2 mutation while endometrioid carcinomas can occur in patients with\nLS.46 The most common ovarian carcinoma is HGSC (approximately 70%) followed by clear cell and", "section": "Definitions", "page_from": 11, "page_to": 11, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "a220aab6555752112f5be411b6494032df31dd34859e5352991623c013b161ee"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000044", "text": "be associated with underlying BRCA1/2 mutation while endometrioid carcinomas can occur in patients with\nLS.46 The most common ovarian carcinoma is HGSC (approximately 70%) followed by clear cell and\nendometrioid.47,48 Mucinous and low grade serous are less common. Approximately 90% of advanced stage\novarian carcinomas (Stage III/IV) are high grade serous in type.47,48 Most primary tubal carcinomas are high\ngrade serous type.\n\nMixed ovarian carcinomas are now considered to be uncommon. It is recommended that all distinct\nmorphological types in an ovarian carcinoma are documented, even if they comprise less than 10% of the\nneoplasm. As stated, mixed carcinomas in the ovary are uncommon, the most prevalent combination being\nclear cell and endometrioid (both of these tumour types often arise in endometriosis). Most neoplasms which\nwere previously classified as mixed serous and endometrioid, and mixed serous and clear cell, represent\nHGSCs with pseudoendometrioid areas and areas of cytoplasmic clearing respectively. In such cases,\nimmunohistochemical markers, especially WT1, may be useful (see Note 18 ANCILLARY STUDIES).", "section": "Definitions", "page_from": 11, "page_to": 11, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "0f9a77e9ca6e1487466fd804b1156145ac60206e8c00909095b2ea6d3f591b7c"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000045", "text": "HGSCs with pseudoendometrioid areas and areas of cytoplasmic clearing respectively. In such cases,\nimmunohistochemical markers, especially WT1, may be useful (see Note 18 ANCILLARY STUDIES).\n\nBorderline tumours should also be typed according to 2020 WHO Classification criteria.3 The most common\ntypes are serous and mucinous. Seromucinous, endometrioid and Brenner types also occur. Clear cell\nborderline tumour should only be diagnosed with the greatest caution, being certain to exclude carcinoma.", "section": "Definitions", "page_from": 11, "page_to": 11, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "48685e1a6c44a38a3c0237b53a5aa40ec5be7ccf1b13f9a5e0cf0289659cfcab"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000046", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 12 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nTable 1: World Health Organization classification of tumours of the ovary.3\n\n a These morphology codes are from the International Classification of Diseases for Oncology, third edition, second\nrevision (ICD-O-3.2).49 Behaviour is coded /0 for benign tumours; /1 for unspecified, borderline, or uncertain behaviour;\n/2 for carcinoma in situ and grade III intraepithelial neoplasia; and /3 for malignant tumours, primary site; and /6 for\nmalignant tumours, metastatic site. This classification is modified from the previous WHO classification, taking into\naccount changes in our understanding of these lesions. Incorporates all relevant changes from the 5th edition Corrigenda\nJune 2021.\n© World Health Organization/International Agency for Research on Cancer. Reproduced with permission.\n\nTable 2: World Health Organization classification of tumours of the fallopian tube.3", "section": "Definitions", "page_from": 12, "page_to": 12, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "29ecc85adb2f464317e21d08e19ff215f48e51ce187ac9f52f5041c26424b1e3"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000047", "text": "June 2021.\n© World Health Organization/International Agency for Research on Cancer. Reproduced with permission.\n\nTable 2: World Health Organization classification of tumours of the fallopian tube.3\n\n a These morphology codes are from the International Classification of Diseases for Oncology, third edition, second\nrevision (ICD-O-3.2).49 Behaviour is coded /0 for benign tumours; /1 for unspecified, borderline, or uncertain behaviour;\n/2 for carcinoma in situ and grade III intraepithelial neoplasia; and /3 for malignant tumours, primary site; and /6 for\nmalignant tumours, metastatic site. This classification is modified from the previous WHO classification, taking into\naccount changes in our understanding of these lesions. Incorporates all relevant changes from the 5th edition Corrigenda\nJune 2021.\n© World Health Organization/International Agency for Research on Cancer. Reproduced with permission.\nDescriptor\nICD-O codesa\nEpithelial tumours\n\nSerous tumours\nBorderline\nSerous borderline tumour NOS\n8442/1\n\nMalignant\nLow grade serous carcinoma\n8460/3\n\nMalignant\nHigh grade serous carcinoma\n8461/3\nMucinous tumours\nBorderline\nMucinous borderline tumour\n8472/1\n\nMalignant", "section": "Definitions", "page_from": 12, "page_to": 12, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "88467a708b24ce59085c8712614c43cf9f195a07a175064a089cbdbab34dff84"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000048", "text": "Serous borderline tumour NOS\n8442/1\n\nMalignant\nLow grade serous carcinoma\n8460/3\n\nMalignant\nHigh grade serous carcinoma\n8461/3\nMucinous tumours\nBorderline\nMucinous borderline tumour\n8472/1\n\nMalignant\nMucinous adenocarcinoma\n8480/3\nEndometrioid tumours\nBorderline\nEndometrioid tumour, borderline\n8380/1\n\nMalignant\nEndometrioid adenocarcinoma NOS\n8380/3\nClear cell tumours\nBorderline\nClear cell borderline tumour\n8313/1\n\nMalignant\nClear cell adenocarcinoma NOS\n8310/3\nSeromucinous tumours\nBorderline\nSeromucinous borderline tumour\n8474/1\nBrenner tumours\nBorderline\nBrenner tumour, borderline malignancy 9000/1\n\nMalignant\nBrenner tumour, malignant\n9000/3\nOther carcinomas\nMalignant\nMesonephric-like adenocarcinoma\n9111/3\n\nMalignant\nCarcinoma, undifferentiated, NOS\n8020/3\n\nMalignant\nDedifferentiated carcinoma\n8020/3\n\nMalignant\nCarcinosarcoma NOS\n8980/3\n\nMalignant\nMixed cell adenocarcinoma\n8323/3\nDescriptor\nICD-O codesa\nEpithelial tumours\n\nEpithelial precursor lesion\nSerous adenofibroma NOS\n9014/0\nEpithelial borderline tumour\nSerous borderline tumour NOS\n8442/1\nMalignant epithelial tumours\nHigh grade serous carcinoma\n8461/3\n\nEndometrioid adenocarcinoma NOS\n8380/3\n\nCarcinosarcoma NOS\n8980/3", "section": "Definitions", "page_from": 12, "page_to": 12, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "55904c8d382f6a0f233bdab06a3ac30c36cdcdcebc354960b57926f1e2c79dd7"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000049", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 13 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nTable 3: World Health Organization classification of tumours of the peritoneum.3\n\na These morphology codes are from the International Classification of Diseases for Oncology, third edition, second\nrevision (ICD-O-3.2).49 Behaviour is coded /0 for benign tumours; /1 for unspecified, borderline, or uncertain behaviour;\n/2 for carcinoma in situ and grade III intraepithelial neoplasia; and /3 for malignant tumours, primary site; and /6 for\nmalignant tumours, metastatic site. This classification is modified from the previous WHO classification, taking into\naccount changes in our understanding of these lesions. Incorporates all relevant changes from the 5th edition Corrigenda\nJune 2021.\n© World Health Organization/International Agency for Research on Cancer. Reproduced with permission.\n       Back\n\nNote 9 – Pattern of invasion (Non-core)\n\nIt is controversial as to whether the pattern of invasion in Stage I mucinous ovarian carcinoma has prognostic", "section": "Definitions", "page_from": 13, "page_to": 13, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "1949c344bdf0cc863facb3e9aac1d5d4746875e6c017cfb965819a94c9c8e727"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000050", "text": "Back\n\nNote 9 – Pattern of invasion (Non-core)\n\nIt is controversial as to whether the pattern of invasion in Stage I mucinous ovarian carcinoma has prognostic\nsignificance; therefore this is a non-core element.50-55 The expansile/confluent/non-destructive pattern of\ninvasion is characterised by architecturally complex glands, cysts or papillae lined by atypical epithelium with\nminimal to no intervening stroma. The destructive/infiltrative pattern is characterised by haphazardly\narranged glands, tubules, nests and cords of malignant cells infiltrating stroma with an associated\noedematous, inflammatory or desmoplastic response. While several studies have shown the expansile pattern\nheralds a better prognosis,50-52,54-57 a population-based registry study of mucinous ovarian carcinomas was not\nable to prognosticate utilising the distinction between the two patterns of invasion.53 It is recommended that\nthe pattern of invasion in mucinous ovarian carcinomas be recorded. The focus of invasion should measure >5\nmm in greatest linear extent; otherwise, this should be considered microinvasion or microinvasive carcinoma.\n       Back\n\nNote 10 – Carcinosarcoma components (Non-core)", "section": "Definitions", "page_from": 13, "page_to": 13, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "ff02cb5c3694f31e06b46b2d2be5b4223d1d9d2185167506cfa642c41b8c1249"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000051", "text": "mm in greatest linear extent; otherwise, this should be considered microinvasion or microinvasive carcinoma.\n       Back\n\nNote 10 – Carcinosarcoma components (Non-core)\n\nThere is little published evidence suggesting any prognostic significance of the different morphological\ncomponents within ovarian carcinosarcomas (although some prognostic evidence exists for uterine\ncarcinosarcomas).58-60 In view of the paucity of studies, the ICCR Ovary Carcinoma Dataset Authoring\nCommittee (DAC) recommends that it would be useful to record the percentage of the epithelial and\nmesenchymal elements as well as the components of the epithelial and mesenchymal (homologous or\nheterologous) elements. This is a recommendation rather than a requirement as collection of these data may\nbe informative for the future prognosis and management of these neoplasms.58-60\n       Back\n\nDescriptor\nICD-O codesa\nEpithelial tumours (of Müllerian type)\n\nSerous borderline tumour NOS\n8442/1\nLow grade serous carcinoma\n8460/3\nHigh grade serous carcinoma\n8461/3", "section": "Definitions", "page_from": 13, "page_to": 13, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "945c9f152bb5c82430303be735b7015505a77a9e399ea2338c3218a09174988f"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000052", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 14 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nNote 11 – Histological tumour grade (Core and Non-core)\n\nHistological grade is part of current European Society for Medical Oncology (ESMO)-European Society of\nGynaecological Oncology (ESGO) management guidelines for endometrioid and mucinous carcinomas.61 Serous\ncarcinomas are now classified as low grade serous or high grade serous,3 and despite the names including the\nterm grade, these are two different histotypes rather than low grade and high grade variants of the same\ntumour type. Hence, grading does not apply to serous carcinomas. Clear cell carcinomas, un-/dedifferentiated\ncarcinomas, anaplastic carcinomas, carcinosarcomas and mesonephric-like carcinomas are aggressive tumours\nand grading does not apply. There is no grading system for malignant Brenner tumours. If chemotherapy has\nbeen administered, tumour grading (and typing) may need to be based on the pre-chemotherapy biopsy.", "section": "Definitions", "page_from": 14, "page_to": 14, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "d69c50df27ba78bcb40c5026f98c94e761011d7348012cef74b2ad83ec387bcb"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000053", "text": "been administered, tumour grading (and typing) may need to be based on the pre-chemotherapy biopsy.\n\nThe independent prognostic significance of grade for ovarian endometrioid carcinomas has only recently been\nvalidated.62 The 1988 FIGO grading system is widely used for grading endometrioid carcinomas of ovarian and\nendometrial origin.13 The FIGO grading system is based on architecture; tumours with <5% non-squamous solid\ncomponent are grade 1, those with 5-50% solid areas are grade 2, and tumours with >50% of solid architecture\nare classified as grade 3.13 When grade 1 and 2 tumours show severe nuclear atypia in the majority of the\ntumour cells (grade 3 nuclei), the histological grade is increased by one.13,63\n\nDedifferentiation in endometrioid carcinoma, sometimes with Switch/Sucrose non-fermenting (SWI/SNF)\nalterations, results in highly aggressive behaviour and such tumours are high grade by definition.64 A significant\nmajority of ovarian endometrioid carcinomas are grade 1 and 2. However, there is a subset of grade 3\nendometrioid carcinomas which should be diagnosed with caution, since a significant proportion of such", "section": "Definitions", "page_from": 14, "page_to": 14, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "04bbf0f35edfd254e209f1cc4c271149d5010fde64f721f3953b98fddaa2a363"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000054", "text": "endometrioid carcinomas which should be diagnosed with caution, since a significant proportion of such\ntumours are in fact HGSC with so called SET features (solid, pseudoendometrioid, transitional cell). IHC is\nuseful in this regard (see Note 18 ANCILLARY STUDIES). The interobserver reproducibility of grading is limited\nand several studies have attempted to improve on it.65-70 There are shortcomings of a primarily architecturally\nbased grading system. Certain growth patterns of endometrioid carcinoma such as spindled with bland nuclear\nfeatures may be over-graded. On the contrary, tumours with non-solid architecture but high grade nuclear\natypia may be under-graded. For example, in a recent study a number of p53 abnormal (p53abn) ovarian\nendometrioid carcinomas with aggressive course were graded as 1.62\n\nAs compared to the FIGO grading system,13 the Silverberg grading system71 was found to correlate better with\nsurvival in a multivariate analysis, although outcome in ovarian endometrioid carcinoma is mostly dictated by\nstage.63 The Silverberg system (Table 4) takes into account nuclear atypia and mitotic activity in addition to", "section": "Definitions", "page_from": 14, "page_to": 14, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "55ba9b0f1aa75ec92ca77b8a3777be8c7d4a57e5da327c2d3b0718fafb9c8ada"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000055", "text": "stage.63 The Silverberg system (Table 4) takes into account nuclear atypia and mitotic activity in addition to\narchitecture. Thus, the scores for architecture (majority glandular=1, papillary=2, solid=3), nuclear atypia\n(mild=1, moderate=2, severe=3), mitotic activity per mm2 of tumour area or in 10 high power fields (HPF)\n(based on each HPF being 0.345 mm2 in area, as per the original study;71 0-3 mitotic figures/mm2 (or 0 to 9\nmitotic figures per 10 HPF) =1, 3-7 mitotic figures/mm2 (or 10 to 24 mitotic figures per 10 HPF) =2, and >7\nmitotic figures/mm2 (or ≥25 mitotic figures per 10 HPF) =3) are added to obtain a score for determining the\nfinal grade (G1: 3 to 5, G2: 6 to 7, G3: 8 to 9). The better performance of the Silverberg system was attributed\nto the better separation of grade 2 from the grade 3 tumours, which had a poor outcome.63", "section": "Definitions", "page_from": 14, "page_to": 14, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "e48e5f0c8106b14bd3ddecae74c2234bbb37f2b88f73bf57809e86ad81094615"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000056", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 15 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nTable 4: The Silverberg grading system.71\nCriterion\nScore\nArchitecture (majority pattern)\n\n  Glandular\n1\n  Papillary\n2\n  Solid\n3\nNuclear atypia\n\n  Mild\n1\n  Moderate\n2\n  Severe\n3\nMitotic count per mm2\n\n  <3 mitotic figures/mm2\n1\n  3-7 mitotic figures/mm2\n2\n  >7 mitotic figures/mm2\n3\nFinal Grade\nTotal Score\n  Grade 1\n3-5\n  Grade 2\n6-7\n  Grade 3\n8-9\n\nThe DAC panel agrees that there is insufficient evidence for a change in the grading system of endometrioid\ncarcinomas and continues to recommend the FIGO grading system.13\n\nIn addition to grading, molecular subtype assignment may further improve outcome prediction in the same\nway as for endometrioid carcinoma of the uterus; this is done with IHC for MMR proteins and p53 and by\nsequencing for exonuclease domain mutations (EDM) of Polymerase epsilon (POLE).62,72\n\nSome management guidelines for mucinous carcinomas require grading.61 The DAC previously suggest that if", "section": "Criterion", "page_from": 15, "page_to": 15, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "83703c802a3fd70ab162a3ad7d81e7494c288a9b646dccbf97d07b3255acd2b3"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000057", "text": "sequencing for exonuclease domain mutations (EDM) of Polymerase epsilon (POLE).62,72\n\nSome management guidelines for mucinous carcinomas require grading.61 The DAC previously suggest that if\ngrading of mucinous carcinomas is undertaken (a non-core element rather than a core element), the same\ngrading system for endometrioid carcinomas should be used. However, a recent study showed no prognostic\nsignificance of the FIGO grading system and reemphasised that mucinous carcinomas only rarely show a solid\ngrowth pattern.73 In this study, the Silverberg grade was significantly associated with survival, although all\nmucinous carcinomas were graded as grade 1 or 2 by the Silverberg system, and none as grade 3.73 The DAC\nnow recommends the Silverberg grading system71 for mucinous carcinomas as a non-core reporting element.\n\nThe same study also proposed a growth-based grading system based on the pattern of invasion.73\nExpansile/confluent invasion or infiltrative invasion ≤10% of the tumour is graded as 1 while infiltrative\ninvasion >10% is graded as 2.73 This was significantly associated with survival in univariable analysis in this", "section": "Criterion", "page_from": 15, "page_to": 15, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "4e6c79264b585ceea18dba0b3926afcbead991326f6f1354f023af6843ee8042"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000058", "text": "invasion >10% is graded as 2.73 This was significantly associated with survival in univariable analysis in this\nrelatively small study of 46 cases.74 This corroborates earlier studies showing that while infiltrative invasion is\nassociated with higher stage, it also predicts higher risk of recurrence at Stage I.53,57,74,75 It is important to note,\nhowever, that an infiltrative pattern of invasion is a characteristic feature of metastatic mucinous carcinoma.\nIn one study, the infiltrative pattern of invasion lost its significant association with survival after metastatic\ncarcinomas to the ovary were excluded.76 If an infiltrative/destructive pattern is present, metastatic carcinoma\nshould carefully be ruled out. The quantification of the infiltrative component as focal (≤10%) or diffuse (>10%)\nmay be recorded to allow more data to be gathered for future studies.\n       Back", "section": "Criterion", "page_from": 15, "page_to": 15, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "f0b4b5175038f713bb9350e4f4180f3edd435744d68c4ab13ef19d4b0a5f33ca"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000059", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 16 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nNote 12 – Borderline tumour - special features (Core and Non-core)\n\nTerminology for ovarian borderline tumours has evolved over several years.40,77 The preferred terminology is\nborderline tumour, for example serous or mucinous borderline tumour, and this has been endorsed in the\n2020 WHO Classification.3 Serous borderline tumours can be of typical or micropapillary subtypes, as per the\nlatest WHO Classification.3 For mucinous, endometrioid, clear cell, Brenner, and seromucinous tumours, the\ndesignation ‘borderline tumour’ is also used in the 2020 WHO Classification.3 The terms ‘low malignant\npotential’ or ‘atypical proliferative’ are not recommended.3 Synonyms formerly used for seromucinous\nborderline tumours include endocervical-type mucinous borderline tumour, Müllerian mucinous borderline\ntumour, and atypical proliferative (borderline) Müllerian tumour.78\n\nDetermining the lowest threshold for the diagnosis of a borderline tumour in the setting of a", "section": "Criterion", "page_from": 16, "page_to": 16, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "e69a7aadabc283d4e4b6cd0f71bed3dd78a7298933095dcc03ecbc48e745aa1a"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000060", "text": "tumour, and atypical proliferative (borderline) Müllerian tumour.78\n\nDetermining the lowest threshold for the diagnosis of a borderline tumour in the setting of a\ncystadenoma/cystadenofibroma with minimal epithelial proliferation can be subjective and quantitative\ncriteria have been suggested: cystadenomas/cystadenofibromas with qualitatively sufficient epithelial\nstratification/complexity involving ≥10% of the epithelial volume are designated as borderline tumours arising\nwithin a cystadenoma/cystadenofibroma.40 A borderline tumour in which the epithelial\nstratification/complexity involves <10% of the epithelial volume should be diagnosed as cystadenoma/\ncystadenofibroma with focal epithelial proliferation.\n\nAs serous borderline tumour can exhibit variable degrees of micropapillary or cribriform architecture, a\ndiagnosis of micropapillary subtype of serous borderline tumour is based on the presence of ≥5 mm of\nconfluent micropapillary (defined as micropapillae five times as long as they are wide) or cribriform growth.3\n\nA standardised quantitative criterion for distinguishing microinvasion from frankly invasive carcinoma within a", "section": "Criterion", "page_from": 16, "page_to": 16, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "39261c5367667f6a7eb7fedfd0e3c53d291c0436169fd6b628a0861a652f7d79"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000061", "text": "A standardised quantitative criterion for distinguishing microinvasion from frankly invasive carcinoma within a\nborderline tumour has not been established, with varying definitions used in different studies, including 1, 2, 3,\n5 and 10 mm2 as the upper limits of microinvasion.40,77,79 The 2020 WHO Classification uses 5 mm2 as a cut-off.3\nSome groups distinguish two patterns of stromal invasion in serous tumours which quantitatively falls short of\nfrankly invasive carcinoma (<5 mm) - conventional ‘microinvasion’ (isolated and/or small clusters of\neosinophilic cells and/ or small papillae cytologically similar to the non-invasive component within clear\nlacunar spaces) and ‘microinvasive carcinoma’ (glandular or micropapillary patterns qualitatively analogous to\nlow grade serous carcinoma (LGSC)).40,77 However, other investigators do not advocate this distinction. Due to\ninsufficient numbers of cases in the literature, definitive conclusions regarding the clinical significance of this\ndistinction cannot be drawn.77,80 Analogous to the situation for serous tumours, some investigators advocate", "section": "Criterion", "page_from": 16, "page_to": 16, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "db6eec2270a5a6982c55f8a37e100bfa28a6a8d560f399d2c5f9eecd3752f64e"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000062", "text": "distinction cannot be drawn.77,80 Analogous to the situation for serous tumours, some investigators advocate\nthe separation of ‘microinvasion’ from ‘microinvasive carcinoma’ in mucinous borderline tumours while others\nuse these two terms interchangeably.79\n\nIn mucinous borderline tumours, intraepithelial carcinoma is diagnosed in non-invasive foci with marked\nnuclear atypia, and is often associated with mitotic activity.40,79 However, the reproducibility of this diagnosis\nhas not been formally analysed. It has recently been suggested that p53 IHC could be used instead or in\nsupport of a diagnosis of intraepithelial carcinoma but this remains to be proven.81 Intraepithelial carcinoma\nfor mucinous borderline tumours is a non-core item for reporting and the term intraepithelial carcinoma is not\napplied to other types of borderline tumour. Mucinous borderline tumours can be associated with mural\nnodules, which are classified as reactive sarcoma-like, anaplastic carcinoma, or sarcoma.\n\nSarcoma-like nodules are composed of a variable mixture of spindled/round mononucleated cells, often\nassociated with marked inflammation.", "section": "Criterion", "page_from": 16, "page_to": 16, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "00da7df40cb45dd191e46c77abf08feadf15f8b1c65603cef6ac86b7f9e62310"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000063", "text": "Sarcoma-like nodules are composed of a variable mixture of spindled/round mononucleated cells, often\nassociated with marked inflammation.\n\nExtra-ovarian implants occur in approximately 20% of serous borderline tumours and are more common with\nexophytic neoplasms. The most important adverse prognostic factor for ovarian serous borderline tumours in\nwhich there is extra-ovarian disease, is the presence of invasive implants, i.e., LGSC, in extra-ovarian tissues as\nthis portends an adverse prognosis, with non-invasive implants having a favourable prognosis. Specifying the\nlocation and size of implants is important for determining the FIGO stage.13 Non-invasive and invasive\nimplants/LGSC may co-exist in the same specimen. Non-invasive implants are subclassified as epithelial or\ndesmoplastic types.40 Epithelial-type non-invasive implants resemble detached fragments of a serous", "section": "Criterion", "page_from": 16, "page_to": 16, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "f4bc6f674e67b6d4a352bcf82cf5a9eb3b47c123e636ffed42a9c27d0854f3e7"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000064", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 17 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nborderline tumour involving extra-ovarian tissues. They do not exhibit infiltration of underlying tissue, and\nthey are often present within mesothelial or epithelial-lined spaces although they may be adherent to the\nserosal surface. Desmoplastic non-invasive implants are composed of glands or papillary clusters within\nfibroblastic or granulation tissue-like stroma, but they do not exhibit infiltration of adjacent tissue. Often these\nare located on serosal surfaces or within septa in the omentum. Note that the presence of isolated individual\nor small clusters of eosinophilic epithelial cells within the stroma is generally considered to be within the\nspectrum of desmoplastic non-invasive implants rather than representing an invasive implant/LGSC.77\n\nThe most widely used criterion for diagnosing extra-ovarian LGSC/invasive implants in a patient with an", "section": "Criterion", "page_from": 17, "page_to": 17, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "7494230fde6568de984b4041474c0313a2be992e159b7768cdc9ca17a23f35e7"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000065", "text": "The most widely used criterion for diagnosing extra-ovarian LGSC/invasive implants in a patient with an\novarian serous borderline tumour is destructive invasion of underlying tissue.82 Invasive implants often feature\nmarkedly crowded epithelial nests, glands or micropapillary clusters with a haphazard arrangement. The nests,\nglands and papillae are sometimes surrounded by clefts.40,77\n\nIn occasional cases, it may not be possible to definitively distinguish non-invasive from invasive implants/LGSC\nand the recommendation is to designate such implants as being of indeterminate type.83 This terminology\nshould only be used sparingly, and obtaining a specialist gynaecological pathology opinion and submitting\nadditional sections for histological examination (if an omentectomy specimen), may be useful.\n\nWhen invasive implants are present this should be diagnosed in the final pathology report as extra-ovarian\nLGSC;40,77,84 this has been endorsed in the 2020 WHO Classification.3 It is unclear whether invasive implants\ninvolving extra-ovarian sites in association with an ovarian serous borderline tumour represent metastases", "section": "Criterion", "page_from": 17, "page_to": 17, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "03d5536c3751edf969f402425dff1088c857fbb807c801440d1595b01d5db895"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000066", "text": "involving extra-ovarian sites in association with an ovarian serous borderline tumour represent metastases\nfrom the serous borderline tumour or an independent primary peritoneal tumour. A number of molecular\nstudies analysing primary ovarian tumours with their associated implants have yielded varying results.77\nHowever, Ardighieri et al (2014) showed in a large population-based cohort has shown that the vast majority\nof implants are clonally related to the primary ovarian tumour.85 Most of the cases from this study were non-\ninvasive implants; however, all 10 invasive implants had the same mutational status (KRAS mutation, BRAF\nmutation, or wild-type KRAS/BRAF) as the corresponding serous borderline tumour, suggesting that invasive\nimplants are clonally related to the primary ovarian tumour as opposed to representing independent primary\nperitoneal lesions.85 Nevertheless, the number of invasive implants evaluated by molecular methods in the\nentire literature is limited. Carcinoma developing in patients with a previous diagnosis of serous borderline\ntumour are mostly LGSCs and most are clonally related to the serous borderline tumour i.e., represent tumour", "section": "Criterion", "page_from": 17, "page_to": 17, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "622b205ed15f098722812581dc65c7c079e0c9d5a866a7099fca994d81bdf63e"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000067", "text": "tumour are mostly LGSCs and most are clonally related to the serous borderline tumour i.e., represent tumour\nprogression.86 From a practical point of view, for cases of invasive implants in association with an ovarian\ntumour diagnosed as serous borderline tumour, it is recommended to consider additional sampling of ovarian\ntissue to demonstrate LGSC or micropapillary serous borderline tumour.87\n\nImplants may also be encountered in the setting of seromucinous borderline tumours, and the same issues for\nserous tumours pertain. In general implants do not occur in the setting of mucinous, endometrioid, clear cell\nor Brenner borderline tumours.\n       Back\n\nNote 13 – Serous tubal intraepithelial carcinoma (STIC) (Core)\n\nRecently, STIC has been implicated in the pathogenesis of extra-uterine HGSC. The evidence indicating that\nSTIC is a precursor of most HGSCs that were formerly considered to be of tubal, ovarian or primary peritoneal\norigin, as well as guidelines for assigning primary site in cases of advanced stage non-uterine, HGSC, have\nalready been provided (see Note 4 HISTOLOGICAL SITES OF TUMOUR INVOLVEMENT). STIC comprises a", "section": "Criterion", "page_from": 17, "page_to": 17, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "9c2a47a243d6940748605c05af75f43976ae0f2dbfc78c0577bb3b8ffb3bad52"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000068", "text": "already been provided (see Note 4 HISTOLOGICAL SITES OF TUMOUR INVOLVEMENT). STIC comprises a\npopulation of cytologically malignant epithelial cells replacing the normal tubal mucosa, most commonly\ninvolving the fimbria, and characterised by increased nuclear to cytoplasmic ratio with rounded nuclei, loss of\ncell polarity, coarsely clumped chromatin, prominent nucleoli and absence of ciliated cells. Additional features\nthat may be present include epithelial stratification, small fracture lines in the epithelium and tufting and\nexfoliation from the tubal surface of small epithelial cell clusters.", "section": "Criterion", "page_from": 17, "page_to": 17, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "8805ac1fc2de00a528c1337c52a5ba7217594369a3c215ba083cbc22660b83db"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000069", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 18 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nThe diagnostic criteria for STIC have evolved and guidelines for diagnosis, which include the use of p53 and Ki-\n67 (MIB1) immunostaining, have been published.88-90 Use of these criteria results in a high degree of inter-\nobserver diagnostic agreement. In discrete fallopian tube mucosal lesions (usually, but not always, located in\nthe fimbria) with high grade atypia in non-ciliated epithelium, the presence of abnormal p53 immunostaining\n(three mutation-type patterns: overexpression, complete absence and cytoplasmic) and high Ki-67\nproliferation index (≥10%) support a diagnosis of STIC. Although immunostains are a valuable adjunct in the\ndiagnosis of isolated lesions of the fallopian tube, they are usually not needed to diagnosis STIC in the context\nof advanced stage HGSC, where comparison between the tubal mucosal lesion and HGSC elsewhere reveals", "section": "Criterion", "page_from": 18, "page_to": 18, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "f5c34818a09aa70f718e5c5308816ab8d3da219139ea6a88b3d627b3c5b62993"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000070", "text": "of advanced stage HGSC, where comparison between the tubal mucosal lesion and HGSC elsewhere reveals\nidentical cytological features, with high grade atypia and numerous mitotic figures. Fallopian tube epithelial\nlesions with atypia that do not meet all the criteria for STIC (e.g., tubal intraepithelial lesion in\ntransition/serous tubal intraepithelial lesion, synonymous terms for lesions that have some but not all features\nof STIC) are of uncertain significance at present with poor reproducibility and these are not reportable\ndiagnoses and should generally not be used in routine practice; additional research is required to determine\nthe clinical significance, if any, of such lesions. Similarly, p53 signatures should not be reported as a diagnosis.\n\nFallopian tube mucosal involvement by uterine or non-gynaecological primary tumours can occur and mimic\nSTIC.91-93 Most cases with unilateral or bilateral HGSC in the ovary and/or STIC or HGSC in the tube but with an\nendometrial serous intraepithelial or invasive carcinoma will represent adnexal metastases from an\nendometrial serous carcinoma (see Note 18 ANCILLARY STUDIES).94 A diagnosis of STIC always requires", "section": "Criterion", "page_from": 18, "page_to": 18, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "1df7ada35aeed5ccafb7252dfe038f1f71d535086e3f48615f3e78a5894a28c7"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000071", "text": "endometrial serous intraepithelial or invasive carcinoma will represent adnexal metastases from an\nendometrial serous carcinoma (see Note 18 ANCILLARY STUDIES).94 A diagnosis of STIC always requires\nconsideration of clinical and pathological findings and the exclusion of secondary involvement of the fallopian\ntube.\n       Back\n\nNote 14 – Peritoneal cytology (Core)\n\nThe results of peritoneal cytology (peritoneal washings or peritoneal fluid) are important for the substaging of\nStage I ovarian tumours (borderline and malignant). Positive peritoneal washings in a Stage I tumour signify\nStage IC3 in the 2014 FIGO Staging System.13 In the previous 2006 FIGO Staging System,95 the results of\nperitoneal cytology were used for the substaging of Stage II neoplasms, but this is no longer the case. Positive\nperitoneal cytology in a Stage I carcinoma may indicate the need for adjuvant therapy in certain cases. Cells of\nLGSC and serous borderline tumour cannot be reliably distinguished in a cytology specimen; in such cases, the\ncytology findings should be correlated with the histopathological findings.\n       Back\n\nNote 15 – Response to neoadjuvant therapy (Non-core)", "section": "Criterion", "page_from": 18, "page_to": 18, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "b6dbe1bdc98d9b401452f840fb18c8b170757826e657935e83e9bab40072b943"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000072", "text": "cytology findings should be correlated with the histopathological findings.\n       Back\n\nNote 15 – Response to neoadjuvant therapy (Non-core)\n\nHistological assessment of chemotherapy response is only applicable to HGSC at this time. An initial study has\ntested and validated the prognostic significance of chemotherapy response criteria, and assessed\nreproducibility in two independent series of tubo-ovarian HGSC.96,97 This three-tier scoring system (the\nChemotherapy Response Score (CRS)) is reproducible, simple to apply in practice, and has been validated in an\ninternational multicentre study.98 This is the grading system currently recommended by the DAC. The method\nis as follows:\n1. Scoring should be carried out on a single haematoxylin and eosin (H&E)-stained section (refer to\ndiscussion of omental sampling in Note 6 Macroscopic description of omentum).\n2. A single block of involved omental tissue that shows the least response to chemotherapy should be\nselected (if there is no residual omental tumour a CRS score of 3 is given - see Table 5).\n3. The amount of viable tumour should be assessed; this may or may not show degenerative changes in", "section": "Criterion", "page_from": 18, "page_to": 18, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "cd0e1124a407159441b35dd21618f5663591397cb4be4d96f7db795aa6e52408"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000073", "text": "selected (if there is no residual omental tumour a CRS score of 3 is given - see Table 5).\n3. The amount of viable tumour should be assessed; this may or may not show degenerative changes in\nthe form of nuclear atypia, smudging of the nuclear chromatin and cytoplasmic clearing.", "section": "Criterion", "page_from": 18, "page_to": 18, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "7a76caffac2d3beb104c45996981a47dfc929bc68d9d37215b3bca82264a5dd0"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000074", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 19 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\n4. The presence of fibrosis may be helpful in marking the site of previous tumour infiltration:\na.\nWhen found in the absence of tumour, fibrosis is likely to indicate regression.\nb.\nIf fibrosis occurs in association with tumour, this may simply reflect tumour-associated\ndesmoplasia rather than regression.\nc.\nHowever, when fibrosis in association with tumour is accompanied by an inflammatory response\n(so-called ‘fibro-inflammatory’ response – fibrosis with associated macrophages and a mixed\npopulation of inflammatory cells), this indicates regression.\nd.\nPsammoma bodies may mark the site of previous tumour and can sometimes appear more\nnumerous because their density increases in areas where tumour has disappeared.\n5. As a guide, >95% of tumour should be viable for a score of 1, and <5% for a score of 3.\n6. In studies to date using this system or a closely related system, a difference in prognosis was shown", "section": "Criterion", "page_from": 19, "page_to": 19, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "68fb45bbf52bafcdbbb4503aaa3ba1cf7b23dde8013e301d73b95b66b32f44f2"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000075", "text": "5. As a guide, >95% of tumour should be viable for a score of 1, and <5% for a score of 3.\n6. In studies to date using this system or a closely related system, a difference in prognosis was shown\nonly when tumours with a CRS score of 1 or 2 were compared with those having a CRS score of 3.96,97\nHowever, the DAC recommends use of the three-tier system to gather more data for future studies.\n7. Note that this system has only been applied to HGSCs to date.\n8. If the omental tissue appears normal, with neither tumour cells nor fibrosis, it is important to\nascertain that there was omental involvement prior to the start of chemotherapy, that has completely\nregressed, by review of the clinical and radiological findings, before assigning a CRS score of 3. If there\nwas no omental involvement prior to starting chemotherapy, then a CRS score cannot be applied.\n\nTable 5: Chemotherapy response score (CRS).96\nScore\nCriterion\nTumour regression\n1\nMainly viable tumour with no or minimal\nregression-associated fibro-inflammatory\nchangesa limited to a few foci\nNo definite or minimal tumour\nresponse identified\n2\nMultifocal or diffuse regression-associated\nfibro-inflammatory changes, a with viable", "section": "Criterion", "page_from": 19, "page_to": 19, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "73e34c112c7713b7e1c028af0bd9a69ee908c36e45cd3d859cc4dda3af040be2"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000076", "text": "changesa limited to a few foci\nNo definite or minimal tumour\nresponse identified\n2\nMultifocal or diffuse regression-associated\nfibro-inflammatory changes, a with viable\ntumour ranging from diffuse sheets, streaks\nor nodules, to extensive regression with\nmultifocal but easily identifiable residual\ntumour.\nModerate response identified\n3\nMainly regression, with few irregularly\nscattered individual tumour cells or cell\ngroups (all measuring less than 2 mm), or no\nresidual tumour identified.\nMarked response with no or\nminimal residual cancer\na Regression associated fibro-inflammatory changes: fibrosis associated with macrophages, including foam cells, mixed\ninflammatory cells and psammoma bodies; to be distinguished from tumour-related inflammation or desmoplasia.\n       Back\n\nNote 16 – Lymph node status (Core)\n\nIn the revised 2014 FIGO Staging System, metastases involving retroperitoneal lymph nodes, in the absence of\nperitoneal spread above the pelvic brim or distant metastases, represent Stage IIIA1 disease.13 This stage is\nfurther subdivided into Stages IIIA1(i) and IIIA1(ii) for nodal metastases ≤10 mm and >10 mm, respectively.", "section": "Criterion", "page_from": 19, "page_to": 19, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "dbfacabe450abe23d0a0b3713916fea78abc2517717cbccde479ce51177f1686"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000077", "text": "further subdivided into Stages IIIA1(i) and IIIA1(ii) for nodal metastases ≤10 mm and >10 mm, respectively.\nFormerly, regional node metastases were a criterion for Stage IIIC disease and this amendment is based upon\nevidence that patients with only nodal metastases (in the absence of peritoneal disease) have a relatively\nfavourable outcome - although it should be noted that the data are based mainly on cases of HGSC.99,100\nPositive extra-abdominal lymph nodes including inguinal metastases represent Stage IVB disease.", "section": "Criterion", "page_from": 19, "page_to": 19, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "e6d0521cc9e0bab0ab2010b5c73602721bae5e888132aaf74556bece01809195"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000078", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 20 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nInternational Federation of Gynaecology and Obstetrics (FIGO) specifically restricts the definition of Stage IIIA1\ndisease to retroperitoneal lymph nodes (pelvic and para-aortic) but does not indicate how tumour spread to\nintraperitoneal nodes (such as those in the mesentery or omentum) should be interpreted, although it would\nbe very unusual to have isolated nodal metastases at these sites.13 According to FIGO (personal\ncommunication), this should be regarded as intra-abdominal disease, i.e., Stage IIIC.101,102 At present there are\nalso limited data to justify the subdivision of Stage IIIA1 according to the size of the nodal metastases.13 It is\nalso not clear how the extent of nodal involvement (≤10 mm or >10 mm) should be measured if the diagnosis\nis based only upon cytological sampling. According to FIGO (personal communication), this should be regarded\nas Stage IIIA(i) disease.", "section": "Criterion", "page_from": 20, "page_to": 20, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "029de11eb21520b50227458444a81d61d3e93b0323731839d4bd3d5cf778822e"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000079", "text": "is based only upon cytological sampling. According to FIGO (personal communication), this should be regarded\nas Stage IIIA(i) disease.\n\nData on lymph node involvement in borderline ovarian tumours is largely restricted to tumours of serous\nsubtype where approximately 25% of fully staged cases will show positive nodes.103,104 While this finding does\nnot appear to influence overall survival, cases with nodular epithelial tumour aggregates >1 mm in extent may\nshow decreased disease-free survival.105 Rarely, LGSC appears to develop within the lymph nodes of patients\nwith ovarian serous borderline tumours.106\n\nAccording to TNM8,107 nodal involvement should be recorded as the presence of isolated tumour cells (ITC,\n<0.2 mm), micrometastases (MIC, 0.2-2 mm) or macrometastases (MAC, >2 mm).\n       Back\n\nNote 17 – Coexistent pathology/Precursor lesions (Non-core)\n\nBorderline and malignant endometrioid, clear cell and seromucinous ovarian tumours may arise from\nendometriosis. Thus, the presence of endometriosis, although not of prognostic or therapeutic significance,\nparticularly if contiguous with the tumour, may assist in determining the histotype in problematic cases.108,109\n       Back", "section": "Criterion", "page_from": 20, "page_to": 20, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "9108eaaf3db8e16caa9bbaeee30a30fa0ffe1688bbfc775afbadf4fd87ee2b4b"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000080", "text": "particularly if contiguous with the tumour, may assist in determining the histotype in problematic cases.108,109\n       Back\n\nNote 18 – Ancillary studies (Non-core)\n\nMorphology remains the mainstay in ovarian carcinoma diagnosis. Diagnostic ancillary testing is currently\nbased primarily on IHC. Diagnostic immunohistochemical markers may assist in establishing a diagnosis of a\nprimary ovarian carcinoma or aid in histotyping. It is beyond the scope of this dataset to present a detailed\nanalysis (sensitivity, specificity, cut-off interpretation) but the most commonly used first-line\nimmunohistochemical panels are discussed. In general, panels of markers are better than reliance on\nindividual markers and it should be remembered that no marker is totally specific or sensitive for any tumour\ntype. Unexpected positive and negative staining reactions may occur. Therefore, the results of\nimmunohistochemical studies should always be interpreted in conjunction with the clinical, gross and\nmicroscopic features.109,110\n\nThe choice of ancillary tests for the distinction of a primary ovarian carcinoma from a metastatic malignancy", "section": "Criterion", "page_from": 20, "page_to": 20, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "8d0bc6d2de1287af7b1429fe221478dcbc42e6298e644ac3abd89a4d12c27e2e"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000081", "text": "microscopic features.109,110\n\nThe choice of ancillary tests for the distinction of a primary ovarian carcinoma from a metastatic malignancy\n(Table 6) depends on its morphological context and can be problematic particularly on small or cytological\nspecimens.", "section": "Criterion", "page_from": 20, "page_to": 20, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "21c219c48777bf3b49608c4f93e11d03c1cb1dcd399ad30fe25590c937cbee96"}
{"doc_id": "iccr-ovary-2nd-edn-v1-bookmark__v00000000", "chunk_id": "000082", "text": "Version 2.0 Published September 2021                                 ISBN: 978-1-922324-25-2                                                       Page 21 of 40\n© 2021 International Collaboration on Cancer Reporting Limited (ICCR).\n\nTable 6: Ancillary tests to distinguish primary ovarian carcinoma from a metastasis.\nComparator #1\nComparator #2\nExpressed/abnormal\nin comparator #1\nExpressed/abnormal\nin comparator #2", "section": "Criterion", "page_from": 21, "page_to": 21, "display_name": "ICCR-Ovary-2nd-edn-v1-bookmark", "version": "v00000000", "created_at": "2025-11-28T06:07:19", "hash": "e713f829e93d4025896a3ff2492499585f339c4035307bad0d2ee69af6a64e07"}
